Piramal Pharma Limited Reports 17% YoY Revenue Growth

• Revenue from Operations: ₹2,270 Cr, up 17 % YoY – growth was broad‑based across all segments: CDMO +19 %, Complex Hospital Generics (CHG) +17 %, and Consumer Healthcare (PCH) +15 %.
• EBITDA: ₹285 Cr, up 72 % YoY, driving the EBITDA margin to 12.5 % (up from 8.5 % in Q1 FY26).
• PAT (after exceptional item): (₹69 Cr) loss, 15 % lower than the (₹82 Cr) loss a year ago, reflecting a narrower bottom‑line despite a one‑time exceptional gain in the prior year.
• Other income rose 53 % to ₹89 Cr; material costs, employee expenses, other expenses, interest and depreciation all increased modestly year‑on‑year.

Operational & Business Highlights

• CDMO: Order inflow strong at Indian and overseas sites; commercial‑scale payload‑linker suite launched in the US and sterile injectable capacity expansion at Lexington (US) on track. New partnership with Ajinomoto Bio‑Pharma Services for next‑gen conjugation technology; maintained Zero OAI status and secured an FDA Establishment Inspection Report for the Sellersville (US) facility.
• Complex Hospital Generics (CHG): Retained 48 % value share in the US sevoflurane market and continued leadership in US intrathecal baclofen; integration of Kenalog® progressing with supplies expected from Q2 FY27; ongoing investments in 505(b)(2) products and in‑licensing/co‑development.
• Consumer Healthcare (PCH): Power Brands grew 23 % YoY, now accounting for 53 % of PCH sales; e‑commerce surged 40 % YoY, contributing 28 % of sales. Launched the i‑choose women’s intimate‑care master brand and invested ~12 % of sales in brand building. Premiumisation, disciplined pricing and cost‑optimization helped offset raw‑material inflation and supported EBITDA performance.
• Quality & Compliance: Sellersville (US) facility passed FDA inspection with an EIR; the company continues to uphold a Zero OAI track record.

Company: Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635)